They are talking about us! Allurion's newsroom

BBC
bloomberg
Daily Mail
Forbes
Tech Crunch
The Boston Globe
The Guardian
The wall street journal
Scientific American
Good Morning Britain
The New-York Times
The first and only procedureless intragastric balloon

The first and only procedureless intragastric balloon for safe and rapid weight-loss

BARIATRIC NEWS - ”Elipse offers a unique and very attractive way of delivering an outpatient weight management solution for those who either don’t qualify for bariatric surgery, or who would prefer not to undergo a more invasive procedure," said Professor David Kerrigan, Bariatric Surgeon, UK

Tablette trickst den Magen aus

Tablette trickst den Magen aus

FRAU IM LEBEN - Durch das zusätzliche Volumen im Bauch werden Sie schneller satt, essen weniger und nehmen ab – bis zu 15 Kilogramm in vier Monaten. Zur Behandlung gehört eine sechsmonatige Ernährungsberatung mit Hilfsmitteln wie einer digitalen Körperfett-Waage und einer App. Der Ballon selbst wird nach vier Monaten automatisch über den Stuhlgang ausgeschieden – völlig schmerzfrei.

Natick firm Allurion raises $34M for international expansion, U.S. launch

Natick firm Allurion raises $34M for international expansion, U.S. launch

WORCESTER BUSINESS JOURNAL - Allurion said it plans to use the funding to continue growing internationally and, if it receives U.S. Food and Drug Administration approval, launch in the United States. Allurion already sells the Elipse Balloon in Europe, the Middle East, and South America. In three years, the company has sold 15,000 balloons, Allurion CEO and co-founder Shantanu Gaur said last September when Allurion moved into a new 10,000-square-foot office and lab on Erie Drive in Natick.

Obesity-focused Allurion scoops up $34M in new funding

Obesity-focused Allurion scoops up $34M in new funding

BIOWORLD - [Company CEO Shantanu Gaur] highlighted that the company’s success with the financing points to the modern consumer, who is researching his or her options on new interventions and experiences. “And more companies, I think, over the next five to 10 years will start treating them not just as patients inside a very complex health care system, but actual consumers who are choosing to go forward with one product or experience over another.” To that end, the consumer is at the center of what his company does.

How can we help?

We’re here to answer any questions you may have.

This website describes our product, which has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device. Our product is not available for sale in the United States. This website also has a Privacy Policy and Terms of Use that may reflect the laws and practices in other countries and jurisdictions, which may differ from those in the United States. We encourage you to review the Privacy Policy and Terms of Use.
APM003 REV 1 DCO0089

I understand